About IBA Molecular
IBA Molecular is a Healthcare company based in Madrid (Spain) founded in 1974, and was acquired by CapVest in December 2015. Radiopharmaceuticals for PET and SPECT are manufactured and distributed. IBA Molecular offers products and services including Radiofármacos PET, Radiofármacos SPECT, and Diagnostic in Vitro. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Iba Molecular Imaging (india) Private Limited.
Company details
IBA Molecular was founded in 1974 in Madrid, Spain, as a specialist in the nuclear medicine sector. Manufacturing and distribution of PET and SPECT radiopharmaceuticals, such as FDG, Fluorometicoline, Fluorodopa, and Florbetaben, were conducted, alongside in vitro diagnostics. Centralized radiopharmacies were established for product delivery. Molypharma was acquired in 2015, and a merger with Mallinckrodts Nuclear Medicine group created Curium Pharma in 2017.
- Headquarters Madrid, Spain
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website ibamolecular.es
- Social LinkedIn
- Acquired by CapVest (Dec 2015)
- Legal Name Iba Molecular Imaging (India) Private Limited
- InvestorsSK Capital
& 1 more
- Acquired by
Products & Services of IBA Molecular
IBA Molecular offers a comprehensive portfolio of products and services, including Radiofármacos PET, Radiofármacos SPECT, and Diagnostic in Vitro.
Radiopharmaceuticals for positron emission tomography diagnostics
Kits and generators for single photon emission computed tomography
Products for in vitro testing in molecular imaging applications
Investors in IBA Molecular
IBA Molecular has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include SK Capital and CapVest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A global private investment firm focused on specialty sectors. | skcapitalpartners.com | New York, United States | ||
CapVest is recognized as a leading private equity investor. | 1999 | capvest.co.uk | London, United Kingdom |
Investor details for IBA Molecular
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of IBA Molecular
3 dated milestones of IBA Molecular across 41 years, from founding to its latest funding, stage changes and deals.
- Founded IBA Molecular is founded.
- Exit Acquired by SK Capital.
- Exit Acquired by CapVest.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iba Molecular
Complete news archive for IBA Molecular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IBA Molecular
IBA Molecular was founded in 1974.
IBA Molecular is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
IBA Molecular was founded in 1974 in Madrid, Spain, as a specialist in the nuclear medicine sector. Manufacturing and distribution of PET and SPECT radiopharmaceuticals, such as FDG, Fluorometicoline, Fluorodopa, and Florbetaben, were conducted, alongside in vitro diagnostics. Centralized radiopharmacies were established for product delivery. Molypharma was acquired in 2015, and a merger with Mallinckrodts Nuclear Medicine group created Curium Pharma in 2017.
IBA Molecular offers Radiofármacos PET, Radiofármacos SPECT, and Diagnostic in Vitro.
IBA Molecular has 2 investors. Key investors include SK Capital, and CapVest.
IBA Molecular operates through Iba Molecular Imaging (India) Private Limited.
Yes. IBA Molecular was acquired by CapVest in December 2015.